Zaks, Tal

Lipid nanoparticles for mRNA delivery

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 4,076

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., et al. (2024) · The Lancet

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 916

Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 798

Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses

Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy

Influenza Virus Research StudiesRNA Interference and Gene Delivery

Cited by 642

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 527

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine

Influenza Virus Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 454

mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

Cafri, G., Gartner, J. J., Zaks, T., Hopson, K., Levin, N., Paria, B. C., Parkhurst, M. R., Yossef, R., Lowery, F. J., Jafferji, M. S., et al. (2020) · Journal of Clinical Investigation

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 427

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

Qian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., et al. (2009) · Cancer Research

Angiogenesis and VEGF in CancerCancer Mechanisms and Therapy

Cited by 350

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

Aliprantis, A. O., Shaw, C. A., Griffin, P., Farinola, N., Railkar, R. A., Cao, X., Liu, W., Sachs, J. R., Swenson, C. J., Lee, H., et al. (2021) · Human Vaccines & Immunotherapeutics

Respiratory viral infections researchSARS-CoV-2 and COVID-19 Research

Cited by 149

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Burris, H. A., Patel, M. R., Cho, D. C., Clarke, J. M., Gutierrez, M., Zaks, T. Z., Frederick, J., Hopson, K., Mody, K., Binanti-Berube, A., et al. (2019) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 144

Abstract CT001: a personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial

Khattak, A., Carlino, M., Meniawy, T., Ansstas, G., Medina, T., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., et al. (2023) · Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 51

Abstract CT210: A Phase I, open-label, multicenter, dose escalation study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral injection alone and in combination with immune checkpoint blockade

Bauer, T., Patel, M., Jimeno, A., Wang, D., McDermott, J., Zacharek, S., Randolph, W., Johansen, L., Hopson, K., Frederick, J., et al. (2019) · Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 15